Carbamide Crystalline Forms for Neuropsychiatric Drug Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for treating neuropsychiatric and neurodegenerative diseases, such as schizophrenia and Parkinson's disease, have limitations in efficacy and bioavailability due to poor solubility and stability, which affects their therapeutic effectiveness.
Innovation Solution
The synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its polymorphs, including crystalline forms like Form C, which are more soluble and stable, allowing for improved bioavailability and therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional compounds are used for treating neuropsychiatric diseases, then therapeutic activity is achieved, but solubility and bioavailability are poor
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of carbamide compounds through systematic variation of substituents at different positions (R1-R6 groups). This structural parameter optimization enhances both solubility and therapeutic activity, resolving the contradiction between poor solubility and therapeutic effectiveness in conventional compounds.
Solution Approach 2:
The invention creates composite molecular structures combining piperidine rings, carbamide linkages, and various aromatic substituents. These composite structures with specific spatial arrangements and functional groups improve bioavailability while maintaining therapeutic activity, addressing the solubility-effectiveness contradiction.
2Reliability
If conventional compounds are used, then some therapeutic activity is achieved, but stability is poor
Solution Approach 1:
The patent optimizes stability by carefully selecting and positioning substituents (R1-R6) on the carbamide core structure. Specific parameter combinations of these substituents enhance metabolic stability and chemical stability while preserving therapeutic activity, resolving the contradiction between activity and stability.
3Quantity of substance
If solubility is improved through chemical modification, then bioavailability increases, but compound complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions (R1-R6) on the carbamide scaffold. Each substituent position is optimized independently to contribute to solubility without requiring complex overall molecular architecture, thus improving solubility while controlling complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of the compound exhibit enhanced solubility and stability, leading to improved bioavailability and therapeutic effectiveness in treating neuropsychiatric and neurodegenerative diseases, with Form C being the most stable and suitable for pharmaceutical formulations.
Implementation Method 1
Another embodiment disclosed herein includes a crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide that exhibits a melting point of about 124° C., determined with Differential Scanning Calorimetry (DSC)
Data Source
AI summary
Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2 -methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.